BRIEF—Positive outcome of European DCP for Penthrox

Companies in UK-based Mundipharma group have announced the positive outcome of the European Decentralised Procedure (DCP) for Penthrox (methoxyflurane) in 22 European countries for the emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain.

Penthrox is a non-opioid based drug-device combination that consists of a small green inhaler and a 3ml vial of methoxyflurane.

Christian Mazzi, chief commercial officer at Mundipharma, said: “This marketing authorization is a major step towards bringing Penthrox, a new, non-opioid based therapeutic, to patients throughout Europe.

“We’re delighted to be able to continue our proud heritage as leaders in pain management with this treatment and we look forward to working with the different reimbursement bodies to make sure patients and hospitals have access to it as soon as possible."

The current DCP outcome approves the use of the treatment in 22 countries including Germany, Italy and Spain. Penthrox is already marketed in 18 nations including Australia, New Zealand, UK, Ireland, France and Belgium.